HutcheonA.W., HeysS.D., SarkarT.K., OgstonK.N., EreminO., WalkerL.G., MillerID: Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial (abstr 11). Breast Cancer Res Treat, 82: S9, 2003.
2.
SmithI.C., HeysS.D., HutcheonA.W., MillerI.D., PayneS., GilbertF.J., Ah-SeeA.K., EreminO., WalkerL.G., SarkarT.K., EggletonS.P., OgstonKN: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol, 20: 1456–1466, 2002.
3.
BearH.D., AndersonS., BrownA., SmithR., MamounasE.P., FisherB., MargoleseR., TheoretH., SoranA., WickerhamD.L., WolmarkN: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 21: 4165–4174, 2003.
4.
NabholtzJ.M., PienkowskiT., MackeyJ., PawlikiM., GuastallaJ.P., VogelC., WeaverC., WalleyB., MartinM., ChapL., TomiakE.M., JuhosE., GuevinR., HowellA., HainsworthJ., FornanderT., BlitzS., GazelS., LoretC., RivaA: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorbicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc ASCO, 21: abstr 141, 2002.
5.
MartinM., PienowskiT., MackeyJ., PawlickiM., GuastallaJ.P., WeaverC., TomiakE., Al-TweigeriT., ChapL., JuhosE., GuevinR., HowellA., FornanderT., HainsworthJ., ColemanR., VinholesJ., ModianoM., PinterT., HughJ., NabholtzJ.M., LoretC., RupinM., BlitzS., RivaA., VogelC: TAC improves disease free and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months of follow-up. Presented at the 26th San Antonio Breast Cancer Symposium, abstr 43, www.sabcs.org.
6.
Anonimous: Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 352: 930–942, 1998.
